BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ichikawa T, Saito K, Yoshioka N, Tanimoto A, Gokan T, Takehara Y, Kamura T, Gabata T, Murakami T, Ito K. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol. 2010;45:133-141. [PMID: 20098330 DOI: 10.1097/rli.0b013e3181caea5b] [Cited by in Crossref: 164] [Cited by in F6Publishing: 53] [Article Influence: 13.7] [Reference Citation Analysis]
Number Citing Articles
1 Munene G, Vauthey JN, Dixon E. Summary of the 2010 AHPBA/SSO/SSAT Consensus Conference on HCC. Int J Hepatol. 2011;2011:565060. [PMID: 21994863 DOI: 10.4061/2011/565060] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
2 Fujita N, Nishie A, Kubo Y, Asayama Y, Ushijima Y, Takayama Y, Moirta K, Shirabe K, Aishima S, Honda H. Hepatocellular carcinoma: clinical significance of signal heterogeneity in the hepatobiliary phase of gadoxetic acid-enhanced MR imaging. Eur Radiol. 2015;25:211-220. [PMID: 25063395 DOI: 10.1007/s00330-014-3349-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
3 Jiang HY, Chen J, Xia CC, Cao LK, Duan T, Song B. Noninvasive imaging of hepatocellular carcinoma: From diagnosis to prognosis. World J Gastroenterol 2018; 24(22): 2348-2362 [PMID: 29904242 DOI: 10.3748/wjg.v24.i22.2348] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 37] [Article Influence: 11.8] [Reference Citation Analysis]
4 Gupta S, Choh NA, Bhatt MG, Wani RA, Rasool Z, Rasool SR. Diffusion-Weighted Imaging: An Exciting and Problem-Solving Tool in Patients with Hepatic Metastases. Indian J Radiol Imaging 2021;31:86-90. [PMID: 34316115 DOI: 10.1055/s-0041-1729490] [Reference Citation Analysis]
5 Haimerl M, Utpatel K, Götz A, Zeman F, Fellner C, Nickel D, Luerken L, Brennfleck F, Stroszczynski C, Scheiter A, Verloh N. Quantification of contrast agent uptake in the hepatobiliary phase helps to differentiate hepatocellular carcinoma grade. Sci Rep 2021;11:22991. [PMID: 34837039 DOI: 10.1038/s41598-021-02499-2] [Reference Citation Analysis]
6 Sugimoto K, Moriyasu F, Shiraishi J, Saito K, Taira J, Saguchi T, Imai Y. Assessment of arterial hypervascularity of hepatocellular carcinoma: comparison of contrast-enhanced US and gadoxetate disodium-enhanced MR imaging. Eur Radiol. 2012;22:1205-1213. [PMID: 22270142 DOI: 10.1007/s00330-011-2372-3] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 4.1] [Reference Citation Analysis]
7 Nadarevic T, Giljaca V, Colli A, Fraquelli M, Casazza G, Miletic D, Štimac D. Computed tomography for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev 2021;10:CD013362. [PMID: 34611889 DOI: 10.1002/14651858.CD013362.pub2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Zhou J, Sun H, Wang Z, Cong W, Wang J, Zeng M, Zhou W, Bie P, Liu L, Wen T, Han G, Wang M, Liu R, Lu L, Ren Z, Chen M, Zeng Z, Liang P, Liang C, Chen M, Yan F, Wang W, Ji Y, Yun J, Cai D, Chen Y, Cheng W, Cheng S, Dai C, Guo W, Hua B, Huang X, Jia W, Li Y, Li Y, Liang J, Liu T, Lv G, Mao Y, Peng T, Ren W, Shi H, Shi G, Tao K, Wang W, Wang X, Wang Z, Xiang B, Xing B, Xu J, Yang J, Yang J, Yang Y, Yang Y, Ye S, Yin Z, Zhang B, Zhang B, Zhang L, Zhang S, Zhang T, Zhao Y, Zheng H, Zhu J, Zhu K, Liu R, Shi Y, Xiao Y, Dai Z, Teng G, Cai J, Wang W, Cai X, Li Q, Shen F, Qin S, Dong J, Fan J. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer 2020;9:682-720. [PMID: 33442540 DOI: 10.1159/000509424] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 8.5] [Reference Citation Analysis]
9 Amin J, Anjum MA, Sharif M, Kadry S, Nadeem A, Ahmad SF. Liver Tumor Localization Based on YOLOv3 and 3D-Semantic Segmentation Using Deep Neural Networks. Diagnostics 2022;12:823. [DOI: 10.3390/diagnostics12040823] [Reference Citation Analysis]
10 Fujiwara N, Tateishi R, Akahane M, Taguri M, Minami T, Mikami S, Sato M, Uchino K, Enooku K, Kondo Y, Asaoka Y, Yamashiki N, Goto T, Shiina S, Yoshida H, Ohtomo K, Koike K. Changes in risk of immediate adverse reactions to iodinated contrast media by repeated administrations in patients with hepatocellular carcinoma. PLoS One 2013;8:e76018. [PMID: 24098420 DOI: 10.1371/journal.pone.0076018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
11 Ding Y, Rao SX, Meng T, Chen C, Li R, Zeng MS. Usefulness of T1 mapping on Gd-EOB-DTPA-enhanced MR imaging in assessment of non-alcoholic fatty liver disease. Eur Radiol. 2014;24:959-966. [PMID: 24463697 DOI: 10.1007/s00330-014-3096-y] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
12 Shin SK, Kim YS, Choi SJ, Shim YS, Jung DH, Kwon OS, Choi DJ, Kim JH. Characterization of small (≤3 cm) hepatic lesions with atypical enhancement feature and hypointensity in hepatobiliary phase of gadoxetic acid-enhanced MRI in cirrhosis: A STARD-compliant article. Medicine (Baltimore) 2017;96:e7278. [PMID: 28723741 DOI: 10.1097/MD.0000000000007278] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
13 Besa C, Kakite S, Cooper N, Facciuto M, Taouli B. Comparison of gadoxetic acid and gadopentetate dimeglumine-enhanced MRI for HCC detection: prospective crossover study at 3 T. Acta Radiol Open 2015;4:2047981614561285. [PMID: 25793110 DOI: 10.1177/2047981614561285] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
14 Hoogenboom TC, Thursz M, Aboagye EO, Sharma R. Functional imaging of hepatocellular carcinoma. Hepat Oncol 2016;3:137-53. [PMID: 30191034 DOI: 10.2217/hep-2015-0005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
15 Okasha HH, Wifi MN, Awad A, Abdelfatah Y, Abdelfatah D, El-Sawy SS, Alzamzamy A, Abou-Elenin S, Abou-Elmagd A, ElHusseiny R, Wahba M, El-Feki MA, Pawlak KM. Role of EUS in detection of liver metastasis not seen by computed tomography or magnetic resonance imaging during staging of pancreatic, gastrointestinal, and thoracic malignancies. Endosc Ultrasound 2021;10:344-54. [PMID: 34558421 DOI: 10.4103/EUS-D-20-00178] [Reference Citation Analysis]
16 Mi P, Kokuryo D, Cabral H, Wu H, Terada Y, Saga T, Aoki I, Nishiyama N, Kataoka K. A pH-activatable nanoparticle with signal-amplification capabilities for non-invasive imaging of tumour malignancy. Nat Nanotechnol 2016;11:724-30. [PMID: 27183055 DOI: 10.1038/nnano.2016.72] [Cited by in Crossref: 270] [Cited by in F6Publishing: 243] [Article Influence: 45.0] [Reference Citation Analysis]
17 Hallinan JT, Venkatesh SK. Gastric carcinoma: imaging diagnosis, staging and assessment of treatment response. Cancer Imaging 2013;13:212-27. [PMID: 23722535 DOI: 10.1102/1470-7330.2013.0023] [Cited by in Crossref: 62] [Cited by in F6Publishing: 49] [Article Influence: 6.9] [Reference Citation Analysis]
18 Shimamoto D, Nishie A, Asayama Y, Ushijima Y, Takayama Y, Fujita N, Shirabe K, Hida T, Kubo Y, Honda H. MR Prediction of Liver Function and Pathology Using Gd-EOB-DTPA: Effect of Liver Volume Consideration. Biomed Res Int. 2015;2015:141853. [PMID: 26609519 DOI: 10.1155/2015/141853] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
19 Haimerl M, Verloh N, Zeman F, Fellner C, Müller-Wille R, Schreyer AG, Stroszczynski C, Wiggermann P. Assessment of clinical signs of liver cirrhosis using T1 mapping on Gd-EOB-DTPA-enhanced 3T MRI. PLoS One. 2013;8:e85658. [PMID: 24392025 DOI: 10.1371/journal.pone.0085658] [Cited by in Crossref: 69] [Cited by in F6Publishing: 59] [Article Influence: 7.7] [Reference Citation Analysis]
20 Jung EM, Friedrich C, Hoffstetter P, Dendl LM, Klebl F, Agha A, Wiggermann P, Stroszcynski C, Schreyer AG. Volume navigation with contrast enhanced ultrasound and image fusion for percutaneous interventions: first results. PLoS One. 2012;7:e33956. [PMID: 22448281 DOI: 10.1371/journal.pone.0033956] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 5.0] [Reference Citation Analysis]
21 Lee JM, Zech CJ, Bolondi L, Jonas E, Kim MJ, Matsui O, Merkle EM, Sakamoto M, Choi BI. Consensus report of the 4th International Forum for Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid Magnetic Resonance Imaging. Korean J Radiol. 2011;12:403-415. [PMID: 21852900 DOI: 10.3348/kjr.2011.12.4.403] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 4.1] [Reference Citation Analysis]
22 Chen YS, Lim WX, Lin AN, Chen CL, Tsang LL, Yu CY, Hsu HW, Chuang YH, Cheng YF, Ou HY. Clinical Impact of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging on Living Donor Liver Transplant. Transplant Proc 2022:S0041-1345(21)00911-8. [PMID: 35022135 DOI: 10.1016/j.transproceed.2021.09.071] [Reference Citation Analysis]
23 Chen C, Zhao H, Fu X, Huang L, Tang M, Yan X, Sun S, Jia W, Mao L, Shi J, Chen J, He J, Zhu J, Qiu Y. Contrast-enhanced computed tomography plus gadolinium-ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging for gross classification of hepatocellular carcinoma. Oncotarget 2017;8:29741-50. [PMID: 28392502 DOI: 10.18632/oncotarget.15712] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
24 Pahwa S, Liu H, Chen Y, Dastmalchian S, O'Connor G, Lu Z, Badve C, Yu A, Wright K, Chalian H, Rao S, Fu C, Vallines I, Griswold M, Seiberlich N, Zeng M, Gulani V. Quantitative perfusion imaging of neoplastic liver lesions: A multi-institution study. Sci Rep 2018;8:4990. [PMID: 29563601 DOI: 10.1038/s41598-018-20726-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
25 Haimerl M, Wächtler M, Platzek I, Müller-Wille R, Niessen C, Hoffstetter P, Schreyer AG, Stroszczynski C, Wiggermann P. Added value of Gd-EOB-DTPA-enhanced Hepatobiliary phase MR imaging in evaluation of focal solid hepatic lesions. BMC Med Imaging 2013;13:41. [PMID: 24289722 DOI: 10.1186/1471-2342-13-41] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
26 Sagrini E, Renzulli M, Pecorelli A, Stefanini F, Piscaglia F. Imaging of Liver Tumors in Patients with Chronic Liver Disease. Curr Radiol Rep 2014;2. [DOI: 10.1007/s40134-014-0056-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
27 Grözinger G, Bitzer M, Syha R, Ketelsen D, Nikolaou K, Lauer U, Horger M. Correlation of magnetic resonance signal characteristics and perfusion parameters assessed by volume perfusion computed tomography in hepatocellular carcinoma: Impact on lesion characterization. World J Radiol 2016; 8(7): 683-692 [PMID: 27551338 DOI: 10.4329/wjr.v8.i7.683] [Reference Citation Analysis]
28 Korkusuz H, Knau L, Kromen W, Huebner F, Hammerstingl R, Lindemayr S, Bihrer V, Piiper A, Vogl TJ. Gadoxetate acid-enhanced MRI of hepatocellular carcinoma in a c-myc/TGFα transgenic mouse model including signal intensity and fat content: initial experience. Cancer Imaging 2012;12:72-8. [PMID: 22418445 DOI: 10.1102/1470-7330.2012.0009] [Reference Citation Analysis]
29 Kanefuji T, Takano T, Suda T, Akazawa K, Yokoo T, Kamimura H, Kamimura K, Tsuchiya A, Takamura M, Kawai H, Yamagiwa S, Aoyama H, Nomoto M, Terai S. Factors predicting aggressiveness of non-hypervascular hepatic nodules detected on hepatobiliary phase of gadolinium ethoxybenzyl diethylene-triamine-pentaacetic-acid magnetic resonance imaging. World J Gastroenterol 2015; 21(15): 4583-4591 [PMID: 25914467 DOI: 10.3748/wjg.v21.i15.4583] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
30 Lee KH, Lee JM, Park JH, Kim JH, Park HS, Yu MH, Yoon JH, Han JK, Choi BI. MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent gadoxetic acid. Korean J Radiol. 2013;14:894-904. [PMID: 24265564 DOI: 10.3348/kjr.2013.14.6.894] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
31 Kang TW, Lee MW, Song KD, Kim M, Kim SS, Kim SH, Ha SY. Added Value of Contrast-Enhanced Ultrasound on Biopsies of Focal Hepatic Lesions Invisible on Fusion Imaging Guidance. Korean J Radiol 2017;18:152-61. [PMID: 28096725 DOI: 10.3348/kjr.2017.18.1.152] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
32 Sano K, Ichikawa T, Motosugi U, Ichikawa S, Morisaka H, Enomoto N, Matsuda M, Fujii H. Outcome of hypovascular hepatic nodules with positive uptake of gadoxetic acid in patients with cirrhosis. Eur Radiol. 2017;27:518-525. [PMID: 27255397 DOI: 10.1007/s00330-016-4423-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
33 Lafaro KJ, Roumanis P, Demirjian AN, Lall C, Imagawa DK. Gd-EOB-DTPA-Enhanced MRI for Detection of Liver Metastases from Colorectal Cancer: A Surgeon's Perspective! Int J Hepatol 2013;2013:572307. [PMID: 23653860 DOI: 10.1155/2013/572307] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
34 Saito K, Ledsam J, Sourbron S, Hashimoto T, Araki Y, Akata S, Tokuuye K. Measuring hepatic functional reserve using low temporal resolution Gd-EOB-DTPA dynamic contrast-enhanced MRI: a preliminary study comparing galactosyl human serum albumin scintigraphy with indocyanine green retention. Eur Radiol. 2014;24:112-119. [PMID: 23949726 DOI: 10.1007/s00330-013-2983-y] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
35 Nakamura Y, Kimura T, Higaki T, Honda Y, Komoto D, Yamagami T, Iida M, Nagata Y, Honda Y, Aikata H, Chayama K, Awai K. Clinical utility of gadoxetate disodium-enhanced hepatic MRI for stereotactic body radiotherapy of hepatocellular carcinoma. Jpn J Radiol 2015;33:627-35. [PMID: 26227061 DOI: 10.1007/s11604-015-0465-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
36 Kukuk GM, Schaefer SG, Fimmers R, Hadizadeh DR, Ezziddin S, Spengler U, Schild HH, Willinek WA. Hepatobiliary magnetic resonance imaging in patients with liver disease: correlation of liver enhancement with biochemical liver function tests. Eur Radiol. 2014;24:2482-2490. [PMID: 25030459 DOI: 10.1007/s00330-014-3291-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
37 Aoki T, Nishida N, Ueshima K, Morita M, Chishina H, Takita M, Hagiwara S, Ida H, Minami Y, Yamada A, Sofue K, Tsurusaki M, Kudo M. Higher Enhancement Intrahepatic Nodules on the Hepatobiliary Phase of Gd-EOB-DTPA-Enhanced MRI as a Poor Responsive Marker of Anti-PD-1/PD-L1 Monotherapy for Unresectable Hepatocellular Carcinoma. Liver Cancer 2021;10:615-28. [PMID: 34950184 DOI: 10.1159/000518048] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Ichikawa T, Sano K, Morisaka H. Diagnosis of Pathologically Early HCC with EOB-MRI: Experiences and Current Consensus. Liver Cancer 2014;3:97-107. [PMID: 24945000 DOI: 10.1159/000343865] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 6.1] [Reference Citation Analysis]
39 Ohki T, Tateishi R, Akahane M, Mikami S, Sato M, Uchino K, Arano T, Enooku K, Kondo Y, Yamashiki N. CT with hepatic arterioportography as a pretreatment examination for hepatocellular carcinoma patients: a randomized controlled trial. Am J Gastroenterol. 2013;108:1305-1313. [PMID: 23629602 DOI: 10.1038/ajg.2013.109] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
40 Motosugi U, Ichikawa T, Sou H, Sano K, Muhi A, Ehman RL, Araki T. Effects of gadoxetic acid on liver elasticity measurement by using magnetic resonance elastography. Magn Reson Imaging 2012;30:128-32. [PMID: 21937180 DOI: 10.1016/j.mri.2011.08.005] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
41 Yeom SK, Lee SW, Cha SH, Chung HH, Je BK, Kim BH, Hyun JJ. Biliary reflux detection in anomalous union of the pancreatico-biliary duct patients. World J Gastroenterol 2012; 18(9): 952-959 [PMID: 22408355 DOI: 10.3748/wjg.v18.i9.952] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
42 Yoneyama T, Fukukura Y, Kamimura K, Takumi K, Umanodan A, Ueno S, Nakajo M. Efficacy of liver parenchymal enhancement and liver volume to standard liver volume ratio on Gd-EOB-DTPA-enhanced MRI for estimation of liver function. Eur Radiol. 2014;24:857-865. [PMID: 24356768 DOI: 10.1007/s00330-013-3086-5] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 5.0] [Reference Citation Analysis]
43 Haimerl M, Wächtler M, Zeman F, Verloh N, Platzek I, Schreyer AG, Stroszczynski C, Wiggermann P. Quantitative evaluation of enhancement patterns in focal solid liver lesions with Gd-EOB-DTPA-enhanced MRI. PLoS One 2014;9:e100315. [PMID: 24950259 DOI: 10.1371/journal.pone.0100315] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
44 Hwang J, Kim SH, Lee MW, Lee JY. Small (≤ 2 cm) hepatocellular carcinoma in patients with chronic liver disease: comparison of gadoxetic acid-enhanced 3.0 T MRI and multiphasic 64-multirow detector CT. Br J Radiol 2012;85:e314-22. [PMID: 22167508 DOI: 10.1259/bjr/27727228] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 4.3] [Reference Citation Analysis]
45 Zhou J, Sun HC, Wang Z, Cong WM, Wang JH, Zeng MS, Yang JM, Bie P, Liu LX, Wen TF, Han GH, Wang MQ, Liu RB, Lu LG, Ren ZG, Chen MS, Zeng ZC, Liang P, Liang CH, Chen M, Yan FH, Wang WP, Ji Y, Cheng WW, Dai CL, Jia WD, Li YM, Li YX, Liang J, Liu TS, Lv GY, Mao YL, Ren WX, Shi HC, Wang WT, Wang XY, Xing BC, Xu JM, Yang JY, Yang YF, Ye SL, Yin ZY, Zhang BH, Zhang SJ, Zhou WP, Zhu JY, Liu R, Shi YH, Xiao YS, Dai Z, Teng GJ, Cai JQ, Wang WL, Dong JH, Li Q, Shen F, Qin SK, Fan J. Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition). Liver Cancer. 2018;7:235-260. [PMID: 30319983 DOI: 10.1159/000488035] [Cited by in Crossref: 186] [Cited by in F6Publishing: 196] [Article Influence: 46.5] [Reference Citation Analysis]
46 Chen BB, Hsu CY, Yu CW, Wei SY, Kao JH, Lee HS, Shih TT. Dynamic contrast-enhanced magnetic resonance imaging with Gd-EOB-DTPA for the evaluation of liver fibrosis in chronic hepatitis patients. Eur Radiol. 2012;22:171-180. [PMID: 21879400 DOI: 10.1007/s00330-011-2249-5] [Cited by in Crossref: 77] [Cited by in F6Publishing: 80] [Article Influence: 7.0] [Reference Citation Analysis]
47 Chanyaputhipong J, Low SC, Chow PK. Gadoxetate Acid-Enhanced MR Imaging for HCC: A Review for Clinicians. Int J Hepatol. 2011;2011:489342. [PMID: 21994860 DOI: 10.4061/2011/489342] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
48 Yim SY, Park BJ, Um SH, Han NY, Sung DJ, Cho SB, Lee SH, Kim MJ, Jung JY, Kim JD, Seo YS, Kim DS, An H, Kim YH. Diagnostic performance of gadoxetic acid (Primovist)-enhanced MR imaging versus CT during hepatic arteriography and portography for small hypervascular hepatocellular carcinoma. Medicine (Baltimore) 2016;95:e4903. [PMID: 27684824 DOI: 10.1097/MD.0000000000004903] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
49 Tomiyama Y, Yoshioka N, Yanai Y, Kawase T, Nishina S, Hara Y, Yoshida K, Korenaga K, Korenaga M, Hino K. Type 1 interferon receptor in peripheral blood mononuclear cells may predict response to intra-arterial 5-fluorouracil + interferon therapy for advanced hepatocellular carcinoma. Hepat Med 2011;3:45-52. [PMID: 24367220 DOI: 10.2147/HMER.S19695] [Reference Citation Analysis]
50 Morana G, Cugini C, Scatto G, Zanato R, Fusaro M, Dorigo A. Use of contrast agents in oncological imaging: magnetic resonance imaging. Cancer Imaging 2013;13:350-9. [PMID: 24060901 DOI: 10.1102/1470-7330.2013.9018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
51 Matsuda M. Clinical value of gadoxetic acid-enhanced magnetic resonance imaging in surgery for hepatocellular carcinoma - with a special emphasis on early hepatocellular carcinoma. World J Hepatol 2015; 7(30): 2933-2939 [PMID: 26730272 DOI: 10.4254/wjh.v7.i30.2933] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
52 Kagen A, Fowler K, Sirlin CB. Insight into hepatocellular carcinoma biology with gadoxetate disodium-enhanced MRI. Hepat Oncol 2014;1:95-105. [PMID: 30190944 DOI: 10.2217/hep.13.11] [Reference Citation Analysis]
53 Semaan S, Vietti Violi N, Lewis S, Chatterji M, Song C, Besa C, Babb JS, Fiel MI, Schwartz M, Thung S, Sirlin CB, Taouli B. Hepatocellular carcinoma detection in liver cirrhosis: diagnostic performance of contrast-enhanced CT vs. MRI with extracellular contrast vs. gadoxetic acid. Eur Radiol 2020;30:1020-30. [PMID: 31673837 DOI: 10.1007/s00330-019-06458-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
54 Ding Y, Rao SX, Chen CZ, Li RC, Zeng MS. Usefulness of two-point Dixon fat-water separation technique in gadoxetic acid-enhanced liver magnetic resonance imaging. World J Gastroenterol 2015; 21(16): 5017-5022 [PMID: 25945017 DOI: 10.3748/wjg.v21.i16.5017] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
55 Joishi D, Ueno A, Tanimoto A, Okuda S, Masugi Y, Emoto K, Okuma K, Sakamoto M, Imai Y, Kuribayashi S. Natural course of hypovascular nodules detected on gadoxetic acid-enhanced MR imaging: presence of fat is a risk factor for hypervascularization. Magn Reson Med Sci 2013;12:281-7. [PMID: 24172788 DOI: 10.2463/mrms.2012-0097] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
56 Frydrychowicz A, Lubner MG, Brown JJ, Merkle EM, Nagle SK, Rofsky NM, Reeder SB. Hepatobiliary MR imaging with gadolinium-based contrast agents. J Magn Reson Imaging. 2012;35:492-511. [PMID: 22334493 DOI: 10.1002/jmri.22833] [Cited by in Crossref: 98] [Cited by in F6Publishing: 82] [Article Influence: 9.8] [Reference Citation Analysis]
57 Aoki T, Nishida N, Ueshima K, Morita M, Chishina H, Takita M, Hagiwara S, Ida H, Minami Y, Yamada A, Sofue K, Tsurusaki M, Kudo M. Higher Enhancement Intrahepatic Nodules on the Hepatobiliary Phase of Gd-EOB-DTPA-Enhanced MRI as a Poor Responsive Marker of Anti-PD-1/PD-L1 Monotherapy for Unresectable Hepatocellular Carcinoma. Liver Cancer 2021;10:615-28. [PMID: 34950184 DOI: 10.1159/000518048] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Bo XW, Xu HX, Wang D, Guo LH, Sun LP, Li XL, Zhao CK, He YP, Liu BJ, Li DD, Zhang K. Fusion imaging of contrast-enhanced ultrasound and contrast-enhanced CT or MRI before radiofrequency ablation for liver cancers. Br J Radiol 2016;89:20160379. [PMID: 27626506 DOI: 10.1259/bjr.20160379] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
59 Kitao A, Matsui O, Yoneda N, Kozaka K, Kobayashi S, Koda W, Gabata T, Yamashita T, Kaneko S, Nakanuma Y, Kita R, Arii S. Hypervascular hepatocellular carcinoma: correlation between biologic features and signal intensity on gadoxetic acid-enhanced MR images. Radiology 2012;265:780-9. [PMID: 23175543 DOI: 10.1148/radiol.12120226] [Cited by in Crossref: 80] [Cited by in F6Publishing: 73] [Article Influence: 8.9] [Reference Citation Analysis]
60 Shan Y, Gao J, Zeng MS, Lin J, Xu PJ. Gadoxetic acid-enhanced magnetic resonance imaging for the detection of small hepatocellular carcinoma (≤ 2.0 cm) in patients with chronic liver disease: A meta-analysis. World J Meta-Anal 2016; 4(4): 95-104 [DOI: 10.13105/wjma.v4.i4.95] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
61 Onishi H, Kim T, Imai Y, Hori M, Nagano H, Nakaya Y, Tsuboyama T, Nakamoto A, Tatsumi M, Kumano S. Hypervascular hepatocellular carcinomas: detection with gadoxetate disodium-enhanced MR imaging and multiphasic multidetector CT. Eur Radiol. 2012;22:845-854. [PMID: 22057248 DOI: 10.1007/s00330-011-2316-y] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 4.6] [Reference Citation Analysis]
62 Hennedige T, Venkatesh SK. Imaging of hepatocellular carcinoma: diagnosis, staging and treatment monitoring. Cancer Imaging. 2013;12:530-547. [PMID: 23400006 DOI: 10.1102/1470-7330.2012.0044] [Cited by in Crossref: 86] [Cited by in F6Publishing: 70] [Article Influence: 9.6] [Reference Citation Analysis]
63 Kanefuji T, Takano T, Suda T, Akazawa K, Yokoo T, Kamimura H, Kamimura K, Tsuchiya A, Takamura M, Kawai H, Yamagiwa S, Aoyama H, Nomoto M, Terai S. Factors predicting aggressiveness of non-hypervascular hepatic nodules detected on hepatobiliary phase of gadolinium ethoxybenzyl diethylene-triamine-pentaacetic-acid magnetic resonance imaging. World J Gastroenterol 2015;21:4583-91. [PMID: 25914467 DOI: 10.3748/wjg.v21.i15.4583] [Reference Citation Analysis]
64 Reimer P, Vosshenrich R. Detection and characterization of liver lesions using gadoxetic acid as a tissue-specific contrast agent. Biologics 2010;4:199-212. [PMID: 20714357 DOI: 10.2147/btt.s6479] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]